GeDDiS: Gemcitabine and Docetaxel Versus Doxorubicin as First-Line Treatment in Advanced Soft-Tissue Sarcoma Last updated on Aug 3, 2026 Previous Trabectedin Next GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
